7. In adults with obesity or overweight with weight-related complications,
AGA suggests using phentermine with lifestyle modifications, compared
with lifestyle modifications alone. (Conditional recommendation, low
certainty evidence)
Implementation considerations:
• Phentermine monotherapy is approved by the Food and Drug Administration
(FDA) for short-term use (12 weeks). However, given the chronic nature of obesity
management, many practitioners use phentermine longer than 12 weeks in an off-
label fashion.
• Phentermine should be avoided in patients with a history of cardiovascular disease
and uncontrolled hypertension.
• Blood pressure and heart rate should be monitored periodically while taking
phentermine.
8. In adults with obesity or overweight with weight-related complications,
AGA suggests using diethylpropion with lifestyle modifications,
compared with lifestyle modifications alone. (Conditional
recommendation, low certainty evidence)
Implementation considerations:
• Diethylpropion monotherapy is approved by the FDA for short-term use (12
weeks). However, given the chronic nature of obesity management, many
practitioners use diethylpropion longer than 12 weeks in an off-label fashion.
• Diethylpropion should be avoided in patients with a history of cardiovascular
disease and uncontrolled hypertension.
• Blood pressure and heart rate should be monitored periodically while taking
diethylpropion.
9. In adults with body mass index (BMI) between 25 and 40 kg/m
2
, AGA
recommends using Gelesis100 oral superabsorbent hydrogel only in the
context of a clinical trial. (No recommendation, knowledge gap)
